These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 19696442)

  • 1. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study.
    Ferrer R; Artigas A; Suarez D; Palencia E; Levy MM; Arenzana A; Pérez XL; Sirvent JM;
    Am J Respir Crit Care Med; 2009 Nov; 180(9):861-6. PubMed ID: 19696442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.
    Dellinger RP; Levy MM; Carlet JM; Bion J; Parker MM; Jaeschke R; Reinhart K; Angus DC; Brun-Buisson C; Beale R; Calandra T; Dhainaut JF; Gerlach H; Harvey M; Marini JJ; Marshall J; Ranieri M; Ramsay G; Sevransky J; Thompson BT; Townsend S; Vender JS; Zimmerman JL; Vincent JL; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
    Crit Care Med; 2008 Jan; 36(1):296-327. PubMed ID: 18158437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
    Micek ST; Isakow W; Shannon W; Kollef MH
    Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department.
    Nguyen HB; Corbett SW; Menes K; Cho T; Daugharthy J; Klein W; Wittlake WA
    Acad Emerg Med; 2006 Jan; 13(1):109-13. PubMed ID: 16365336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the effect of the Surviving Sepsis Campaign treatment guidelines on clinical outcomes in a community hospital.
    Patel GW; Roderman N; Gehring H; Saad J; Bartek W
    Ann Pharmacother; 2010 Nov; 44(11):1733-8. PubMed ID: 20978215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resuscitation bundle compliance in severe sepsis and septic shock: improves survival, is better late than never.
    Coba V; Whitmill M; Mooney R; Horst HM; Brandt MM; Digiovine B; Mlynarek M; McLellan B; Boleski G; Yang J; Conway W; Jordan J;
    J Intensive Care Med; 2011; 26(5):304-13. PubMed ID: 21220270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated protein C and septic shock: a propensity-matched cohort study*.
    Rimmer E; Kumar A; Doucette S; Marshall J; Dial S; Gurka D; Dellinger RP; Sharma S; Penner C; Kramer A; Wood K; Ronald J; Kumar A; Turgeon AF; Houston DS; Zarychanski R;
    Crit Care Med; 2012 Nov; 40(11):2974-81. PubMed ID: 22932397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time- and fluid-sensitive resuscitation for hemodynamic support of children in septic shock: barriers to the implementation of the American College of Critical Care Medicine/Pediatric Advanced Life Support Guidelines in a pediatric intensive care unit in a developing world.
    Oliveira CF; Nogueira de Sá FR; Oliveira DS; Gottschald AF; Moura JD; Shibata AR; Troster EJ; Vaz FA; Carcillo JA
    Pediatr Emerg Care; 2008 Dec; 24(12):810-5. PubMed ID: 19050666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Masseter tissue oxygen saturation predicts normal central venous oxygen saturation during early goal-directed therapy and predicts mortality in patients with severe sepsis.
    Colin G; Nardi O; Polito A; Aboab J; Maxime V; Clair B; Friedman D; Orlikowski D; Sharshar T; Annane D
    Crit Care Med; 2012 Feb; 40(2):435-40. PubMed ID: 22020233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
    Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
    Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of fluid resuscitation with synthetic colloids or crystalloids alone on shock reversal, fluid balance, and patient outcomes in patients with severe sepsis: a prospective sequential analysis.
    Bayer O; Reinhart K; Kohl M; Kabisch B; Marshall J; Sakr Y; Bauer M; Hartog C; Schwarzkopf D; Riedemann N
    Crit Care Med; 2012 Sep; 40(9):2543-51. PubMed ID: 22903091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of treatments for severe sepsis: data from the bundle implementation programs.
    Ferrer R; Artigas A
    Minerva Anestesiol; 2011 Mar; 77(3):360-5. PubMed ID: 21441890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of bundles in sepsis care.
    Hurtado FJ; Nin N
    Crit Care Clin; 2006 Jul; 22(3):521-9, x. PubMed ID: 16893737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.
    Dellinger RP; Levy MM; Carlet JM; Bion J; Parker MM; Jaeschke R; Reinhart K; Angus DC; Brun-Buisson C; Beale R; Calandra T; Dhainaut JF; Gerlach H; Harvey M; Marini JJ; Marshall J; Ranieri M; Ramsay G; Sevransky J; Thompson BT; Townsend S; Vender JS; Zimmerman JL; Vincent JL
    Intensive Care Med; 2008 Jan; 34(1):17-60. PubMed ID: 18058085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation.
    Laterre PF; Abraham E; Janes JM; Trzaskoma BL; Correll NL; Booth FV
    Crit Care Med; 2007 Jun; 35(6):1457-63. PubMed ID: 17452935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
    Laterre PF; Levy H; Clermont G; Ball DE; Garg R; Nelson DR; Dhainaut JF; Angus DC
    Crit Care Med; 2004 Nov; 32(11):2207-18. PubMed ID: 15640632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of the effect of fluid resuscitation as guided either by lactate clearance rate or by central venous oxygen saturation in patients with sepsis].
    Yu B; Tian HY; Hu ZJ; Zhao C; Liu LX; Zhang Y; Zhu GJ; Wang LT; Wu XH; Li J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Oct; 25(10):578-83. PubMed ID: 24119693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recommendations for management of severe sepsis and septic shock. Surviving sepsis campaign].
    Martin C; Garnier F; Vallet B
    Ann Fr Anesth Reanim; 2005 Apr; 24(4):440-3. PubMed ID: 15826800
    [No Abstract]   [Full Text] [Related]  

  • 20. A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study.
    Vincent JL; Laterre PF; Decruyenaere J; Spapen H; Raemaekers J; Damas F; Rogiers P; Sartral M; Haentjens T; Nelson D; Janes J
    Acta Clin Belg; 2008; 63(1):25-30. PubMed ID: 18386762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.